Expanded partnership highlights the parties' emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med's expertise in the development of 212 Pb-based TAT and vast proprietary supply ...
Correcting & Replacing: Y-mAbs Therapeutics, Inc. is re-issuing in entirety its press release, originally issued on January 10, 2025 at 7:05 a.m. ET, to correct a scrivener's error in the presentation ...
What's on the horizon for the life sciences industry? Robin Johnson, PharmD, Gene Therapy Submissions Lead, inSeption Group What unique challenges do gene therapy submissions face compared to ...